Review

N-Terminal Regions of Prion Protein: Functions and Roles in Prion Diseases

Hideyuki Hara and Suehiro Sakaguchi *

Division of Molecular Neurobiology, The Institute for Enzyme Research (KOSOKEN), Tokushima University, 3-18-15 Kuramoto, Tokushima 770-8503, Japan; hara@tokushima-u.ac.jp
* Correspondence: sakaguchi@tokushima-u.ac.jp; Tel.: +81-88-633-7438

Received: 15 August 2020; Accepted: 27 August 2020; Published: 28 August 2020

Abstract: The normal cellular isoform of prion protein, designated PrPC, is constitutively converted to the abnormally folded, amyloidogenic isoform, PrPSc, in prion diseases, which include Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in animals. PrPC is a membrane glycoprotein consisting of the non-structural N-terminal domain and the globular C-terminal domain. During conversion of PrPC to PrPSc, its 2/3 C-terminal region undergoes marked structural changes, forming a protease-resistant structure. In contrast, the N-terminal region remains protease-sensitive in PrPSc. Reverse genetic studies using reconstituted PrPC-knockout mice with various mutant PrP molecules have revealed that the N-terminal domain has an important role in the normal function of PrPC and the conversion of PrPC to PrPSc. The N-terminal domain includes various characteristic regions, such as the positively charged residue-rich polybasic region, the octapeptide repeat (OR) region consisting of five repeats of an octapeptide sequence, and the post-OR region with another positively charged residue-rich polybasic region followed by a stretch of hydrophobic residues. We discuss the normal functions of PrPC, the conversion of PrPC to PrPSc, and the neurotoxicity of PrPSc by focusing on the roles of the N-terminal regions in these topics.

Keywords: prion protein; prion; prion disease; neurodegeneration; protein conformation

1. Introduction

Conformational conversion of the normal cellular isoform of prion protein, designated PrPC, to the abnormally folded, amyloidogenic isoform, PrPSc, is a key pathogenic event in prion diseases, a group of fatal neurodegenerative disorders that include Creutzfeldt–Jakob disease (CJD) in humans, scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, and chronic wasting disease in deer [1–4]. These diseases are pathologically characterized by neuronal cell loss, spongiform degeneration, gliosis, and PrPSc accumulation in the brain [5]. Prions, or proteinaceous infectious particles, are the causative agents of these diseases [6,7]. It is believed that prions consist of, if not entirely, PrPSc molecules, and catalyze conformational conversion of PrPC to PrPSc through a seeded protein polymerization mechanism, eventually propagating PrPSc or prions themselves [6,7]. Indeed, it has been shown that mice devoid of PrPC (Prnp−/−) are resistant to prion infection, neither propagating prions nor PrPSc in their brains nor developing disease even after intracerebral inoculation with prions [8–11].

PrPC is a highly conserved, glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein among mammalian species [12]. It is expressed most abundantly in the central nervous system, particularly by neurons, and to a lesser extent in other non-neuronal tissues, such as the lymphoreticular system, lung, and kidney [13]. PrPC consists of two domains; the highly flexible, nonstructural N-terminal (residues 23–120) and the globular C-terminal (residues 121–231) [14–16] (Figure 1A). The globular C-terminal domain is composed of three α-helices and two short anti-parallel β-sheets. Upon conversion to PrPSc, PrPC undergoes marked structural changes in its 2/3 C-terminal region to
form a proteinase K (PK)-resistant structure, while most regions of the N-terminal domain remain PK-sensitive [13]. Reverse genetic studies using reconstituted Prnp^0/0 mice and various mutant PrP molecules have revealed that the N-terminal domain has an important role not only in the normal function of PrP\textsuperscript{C} but also in the conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc}. The N-terminal domain includes several characteristic regions, such as the so-called polybasic region (residues 23–31), which is rich in positively charged residues, the octapeptide repeat (OR) region (residues 51–90) consisting of five repeats of an octapeptide sequence, and the post-OR region (residues 91–120) including the second polybasic region followed by a stretch of hydrophobic amino acid residues [1–4] (Figure 1A). Here we discuss the role of each N-terminal region in the normal function of PrP\textsuperscript{C}, the conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc}, and the neurotoxicity of PrP\textsuperscript{Sc}.

2. The N-Terminal Domain in the Function of PrP\textsuperscript{C}

2.1. Biosynthesis of PrP\textsuperscript{C}

The gene for PrP\textsuperscript{C}, termed Prnp, in human and mouse consists of 2 and 3 exons and resides on chromosome 20 and 2, respectively. The protein coding sequence lies within the last single exon [17,18]. PrP\textsuperscript{C} is synthesized as a precursor protein in the endoplasmic reticulum (ER). The N-terminal and C-terminal sequences, which are rich in hydrophobic residues, are removed as a signal peptide sequence and a GPI-anchor signal sequence, respectively, in the ER (Figure 1A) [17,18]. PrP\textsuperscript{C} also undergoes several post-translational modifications en route to the cell surface, including a GPI anchor attachment at the C-terminus, N-glycosylation at two sites, and formation of a disulfide bond in the C-terminal domain (Figure 1A) [19–24]. On the cell surface, PrP\textsuperscript{C} is predominantly localized at the so-called “raft” domains and constitutively internalized via clathrin- and caveolae-dependent endocytosis (Figure 1B) [25–27]. Some of the internalized PrP\textsuperscript{C} molecules are recycled to the cell surface and others are trafficked to lysosomes for degradation (Figure 1B) [28,29].

![Figure 1](image_url)

**Figure 1.** Structure and biosynthesis of PrP\textsuperscript{C}. (A) Structural configuration of PrP\textsuperscript{C}. Arabic numbers indicate positions of amino acids. (B) Biosynthetic pathways of PrP\textsuperscript{C}, including the vesicle transport pathway from the ER to the plasma membrane, particularly raft domains, and the clathrin- or caveolae-dependent endocytic pathway, which connects to recycling pathway or degradation pathway to lysosomes.
Copper is known to bind to the OR region and induce the clathrin-dependent internalization of PrPC [30]. It has been suggested that copper binding could cause conformational changes in the OR region and thereby dissociate PrPC from conjectural molecules located at raft domains, and that dissociated PrPC then moves to non-raft domains, where it interacts with other conjectural non-raft molecules through the N-terminal polybasic region to be endocytosed via clathrin-coated vesicles [30]. We have shown that sortilin, a type I glycoprotein in the vacuolar protein sorting 10 protein family, interacts with the N-terminal domain of PrPC and functions as a sorting receptor for lysosomal degradation of PrPC [31]. Sortilin also interacts with PrPSc and facilitates its lysosomal degradation [31]. We also have shown that sortilin-knockout mice develop prion disease with shorter incubation times and rapid brain accumulation of PrPSc after inoculation with prions, compared to control wild-type (WT) mice [31], suggesting that the sortilin-mediated trafficking of PrPC and PrPSc to lysosomes could be a host defense mechanism in prion diseases. Low-density lipoprotein receptor-related protein 1 has also been reported as a cargo receptor for PrPC for transport from the Golgi apparatus to the cell surface and from the cell surface to endosomes [32].

2.2. Various Abnormal Phenotypes Are Spontaneously Observed in Prnp0/0 Mice

Prnp0/0 mice are born with no obvious defects, indicating that PrPC could be dispensable for embryonic development [11,33,34]. However, various neurophysiological and neuropathological abnormalities have been reported in Prnp0/0 mice, including poor performance in certain behavioral tests [35], impaired long-term potentiation (LTP) in the hippocampal CA1 neurons [36], altered sleep and circadian rhythms [37], demyelination in spinal cords and peripheral nerves [38], and abnormal olfactory function [39,40]. These results suggest that PrPC is involved in various neuronal functions. However, normal LTP in Prnp0/0 mice has been reported by other investigators [41].

2.3. The OR Region in the Cell-Protective Role of PrPC

We and others have shown that Prnp0/0 mice are vulnerable to ischemic brain, heart, or kidney damage, displaying higher apoptotic cell death and higher oxidative stress in the damaged tissues [42–46]. We also recently reported that Prnp0/0 mice are highly sensitive to infection with influenza A viruses (IAVs), showing higher morbidity and mortality with higher inflammation, higher apoptotic cell death, and higher oxidative stress in their lungs [47]. Treatment with a scavenger for reactive oxygen species (ROS) or an inhibitor for ROS-generating xanthine oxidase rescued Prnp0/0 mice from lethal IAV infection [47]. In contrast, PrP molecules lacking the OR region failed to protect Prnp0/0 mice from lethal IAV infection and ischemic brain damage [47,48]. These results suggest that PrPC could play a cell-protective role against oxidative stress through the OR region. The OR region is known to bind copper [49]. Indeed, the copper content and enzymatic activity of copper/zinc-dependent superoxide dismutase (SOD) were lower in Prnp0/0 lungs and brains than in control WT tissues [47,49]. It is thus possible that PrPC could function as a transporter of the OR region-bound copper to copper/zinc-SOD, thereby regulating enzyme activity and eventually protecting from oxidative stress. It was reported that PrPC itself might have SOD-like activity [50]. However, other investigators have failed to detect SOD activity in PrPC in vitro and in vivo [51,52].

The OR region is also suggested to be involved in other cell-protective mechanisms of PrPC. Overexpression of PrPC, but not an OR-lacking PrP molecule, was shown to protect against Bax-mediated apoptosis in human primary neurons [53], suggesting that PrPC could function as an anti-apoptotic molecule through the OR region. Oh et al. also reported that autophagy was activated in Prnp0/0 hippocampal neuronal cultured cells under serum deprivation, and that expression of PrPC prevented the activation of autophagy in the cells, but an OR-deleted PrP mutant did not [54], suggesting that PrPC could regulate autophagy activity in neuronal cells through the OR region. It remains to be determined if these functions of PrPC are attributable to the activation of copper/zinc-SOD.
2.4. The Polybasic Region in the Function of PrP\textsuperscript{C}

The polybasic region is also suggested to be involved in the anti-oxidative activity of PrP\textsuperscript{C}. Oxidative stress was shown to enhance cleavage of PrP\textsuperscript{C}, releasing the N-terminal fragment, termed N2, which encompasses residues 23–89 including the polybasic region [55], and the N2 fragment protected neuronal cells against oxidative stress through stimulation of MEK1 signaling [56]. Two proline residues in the polybasic region were shown to be important for the N2-mediated anti-oxidative activity [55]. Other roles have also been reported for the polybasic region including that it is involved in mediating the interaction of PrP\textsuperscript{Sc} with tubulin or glycosaminoglycan [57–60], the ß-secretase-mediated cleavage of the Alzheimer’s amyloid precursor protein [61], and DNA repair [62].

3. The N-Terminal Domain of PrP\textsuperscript{C} in Prion Disease

3.1. The Polybasic Region in Prion Disease

Reconstituted Prnp\textsuperscript{0/0} mice by transgenic introduction of a mutant PrP with a deletion of the polybasic region residues 23–31, designated Tg(PrP\textsuperscript{Δ23–31})/Prnp\textsuperscript{0/0} mice, were shown to develop prion disease with markedly elongated incubation times and delayed accumulation of PrP\textsuperscript{Sc}\textsuperscript{Δ23–31} in their brains after inoculation with RML scrapie prions (Table 1) [63]. PrP\textsuperscript{Sc}\textsuperscript{Δ23–31} accumulated in the brains of Tg(PrP\textsuperscript{Δ23–31})/Prnp\textsuperscript{0/0} mice showed similar resistance to PK to WT PrP\textsuperscript{Sc} [63], suggesting that the polybasic region does not affect the PK-resistance of PrP\textsuperscript{Sc}. These results suggest that the polybasic region could play a crucial role in the pathogenesis of prion diseases. We have shown that Tg(PrP\textsuperscript{Δ25–50})/Prnp\textsuperscript{0/0} mice developed disease without elongated incubation times after infection with RML and 22L prions (Table 1) [64], suggesting that the remaining residues 23 and 24 in PrP\textsuperscript{Δ23–50} could be enough for the polybasic region to support prion pathogenesis. However, it was reported that incubation times were only slightly longer or not elongated at all in Tg(PrP\textsuperscript{Δ23–26})/Prnp\textsuperscript{0/0} mice after infection with 127S and LA19K scrapie prions and BSE prions (Table 1) [65]. PrP\textsuperscript{Δ23–26} includes intact residues 27–31, but lacks residues 23 and 24 in the polybasic region. It is thus possible that the polybasic region might require that both residues 23–24 and 27–31 are intact to fully support prion pathogenesis [64]. Consistent with this idea, mutations of lysine residues at positions 24 and 27 together with a mutation of an arginine residue at position 25 rendered ovine PrP highly resistant to 127S and LA19K scrapie prions and BSE prions (Table 1) [65]. PrP\textsuperscript{Δ23–26} includes intact residues 27–31, but lacks residues 23 and 24 in the polybasic region. It is thus possible that the polybasic region might require that both residues 23–24 and 27–31 are intact to fully support prion pathogenesis [64]. Consistent with this idea, mutations of lysine residues at positions 24 and 27 together with a mutation of an arginine residue at position 25 rendered ovine PrP highly resistant to 127S and LA19K scrapie prions and BSE prions (Table 1) [65]. PrP\textsuperscript{Δ23–26} includes intact residues 27–31, but lacks residues 23 and 24 in the polybasic region. It is thus possible that the polybasic region might require that both residues 23–24 and 27–31 are intact to fully support prion pathogenesis [64]. Consistent with this idea, mutations of lysine residues at positions 24 and 27 together with a mutation of an arginine residue at position 25 rendered ovine PrP highly resistant to 127S and LA19K scrapie prions and BSE prions (Table 1) [65].

Table 1. Effects of various mutations in the polybasic region of PrP\textsuperscript{C} on acquired prion diseases.

| Disease Type | PrPs          | Amino Acid Sequence of the Polybasic Region (Residues 23–31) | Susceptibility to Prions                                      | References |
|--------------|---------------|-------------------------------------------------------------|--------------------------------------------------------------|------------|
| Acquired prion disease | WT PrP        | KKRPKPGGW                                                   | Normal                                                       |            |
|               | PrPA23–31     | -- -- -- --                                                  | Markedly reduced to RML scrapie prions.                     | [63]       |
|               | PrPA25–50     | KK-- -- --                                                  | Not reduced to RML and 22L scrapie prions.                  | [64]       |
|               | PrPA23–26     | -- -- -- KPGGW                                               | Only slightly or not reduced to 127S and LA19K scrapie prions and BSE prions. | [65]       |
|               | PrP-M         | KQHPHPGGW                                                   | Markedly reduced to 127S and LA19K prions and BSE prions.   |            |
|               | PrP3K3A       | AARPAPGGW                                                   | Markedly reduced to RML and 22L scrapie prions.             | [66]       |

\(^1\) Amino acids are indicated by single letters. Underline letters indicate amino acids mutated.
3.2. The OR Region in Prion Disease

Insertion of various numbers of an OR sequence, ranging from one to nine, and deletion of one OR sequence in the OR region have been identified in patients with hereditary CJD [67]. Brain homogenates from patients with five, seven, or eight extra OR sequences in PrP can transmit the disease to animals after intracerebral inoculation [68]. This suggests that disruption of the integrity of the OR region by the insertion or deletion of the OR sequence could cause structural instability of mutated PrPs, ultimately leading to their spontaneous conversion to pathogenic, infectious PrPs. We failed to detect PK-resistant PrP in the brains of Tg(PrPΔOR)/Prnp<sup>0/0</sup> mice, which express PrP with a deletion of the OR region alone (Table 2) [69,70], suggesting that spontaneous conversion of mutated PrPs with extra OR sequences to PK-resistant PrPs could be due to gain-of-function, but not due to loss-of-function, of the mutated OR region. Consistent with this, Tg(PG14)/Prnp<sup>0/0</sup> mice, which express a PrP mutant with nine extra OR sequences in the OR region, developed spontaneous cerebellar neurodegeneration including granule cell death, with very slight but substantial accumulation of PK-resistant PrP<sub>Sc</sub>PG14 in their brains (Table 2) [71,72]. However, PrP<sup>Sc</sup>-PG14 had no prion infectivity in animal bioassays (Table 2) [73]. Also, transgenic expression of bovine PrP with four extra OR sequences, or bo10OR-PrP, caused a slowly progressive neurological disorder with ataxia, vaculization, gliosis, and cerebellar granule cell loss in Prnp<sup>0/0</sup> mice (Table 2) [74]. Insoluble and slightly PK-resistant 10OR-PrP<sub>Sc</sub> molecules accumulated in their brains, but no prion infectivity was found associated with the insoluble 10OR-PrP<sub>Sc</sub> (Table 2) [74]. These results indicate that PrP<sub>PG14</sub> and bo10OR-PrP spontaneously convert to PrP<sub>Sc</sub>PG14 and 10OR-PrP<sub>Sc</sub>, respectively, with structural features shared with PrP<sub>Sc</sub> that are responsible for the neurotoxicity but not prion infectivity. These results also suggest that the structural features of PrP<sub>Sc</sub> that contribute to its neurotoxicity and prion infectivity are not identical.

### Table 2. Effects of various mutations in the OR region of PrP<sup>C</sup> on hereditary and acquired prion diseases.

| Disease Type           | PrPs      | Number of the OR Sequence | Clinicopathological Features                                                                 | References |
|------------------------|-----------|---------------------------|------------------------------------------------------------------------------------------------|------------|
| Hereditary prion disease | PG14      | 14<sup>1</sup>             | • Spontaneously develop cerebellar neurodegeneration. • Accumulate very slightly but substantially PK-resistant PrP<sub>Sc</sub>PG14 in the brain. • No prion infectivity associated with PrP<sub>Sc</sub>PG14. | [71–73]    |
|                        | Bo10OR-PrP| 10<sup>2</sup>             | • Accumulate insoluble and slightly PK-resistant 10OR-PrP<sub>Sc</sub> in their brains. • No prion infectivity associated with 10OR-PrP<sub>Sc</sub>. | [74]       |
| Acquired prion disease | PrPΔOR    | 0<sup>1</sup>              | • Reduced to BSE prions, but not to RML and 22L. scrapie prions. | [70]       |
|                        | Bo7OR-PrP | 7<sup>2</sup>              | • Increased to BSE prions. | [75]       |
|                        | Bo10OR-PrP| 10<sup>2</sup>             | • Increased to BSE prions. | [74]       |
|                        | PrP(TetraH>G)| 5<sup>1</sup> (with 4 histidine residues mutated to glycine residues) | • Reduced to RML prions. | [76]       |

<sup>1</sup> Normal mouse PrP<sup>C</sup> contains 5 repeats of the OR sequence.  
<sup>2</sup> Normal bovine PrP<sup>C</sup> contains 6 repeats of the OR sequence.

The OR region is also involved in prion infection. We have shown that Tg(PrPΔOR)/Prnp<sup>0/0</sup> mice are highly resistant to BSE prions (Table 2) [70]. They developed the disease with markedly elongated incubation times with delayed accumulation of PrP<sup>Sc</sup>ΔOR in their brains after inoculation with BSE prions (Table 2) [70]. Consistent with our results, an increasing number of OR insertions contrarily enhances BSE pathogenesis in mice. Prnp<sup>0/0</sup> mice expressing bovine PrP with one extra OR sequence had shortened incubation times when compared with Prnp<sup>0/0</sup> mice expressing WT bovine PrP, or bo6OR-PrP, after infection with BSE prions (Table 2) [75]. BSE-inoculated Tg(bo10OR-PrP)/Prnp<sup>0/0</sup> mice were also shown to have further shortened incubation times when compared to BSE-inoculated
Tg(bo6OR-PrP)/Prnp0/0 mice (Table 2) [74]. These results suggest that the OR region could play a crucial role in BSE prions during the conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc}. In contrast, Tg(PrP\Delta OR)/Prnp0/0 mice remained susceptible to RML and 22L scrapie prions, developing the disease without elongated incubation times with slightly less PrP\textsuperscript{Sc}ΔOR in their brains after infection with RML and 22L prions (Table 2) [70], suggesting that the OR region might be involved in prion pathogenesis in a strain-dependent manner. However, Prnp0/0 mice expressing PrP with histidine residues in the OR region replaced by glycine residues, termed PrP(TetraH>G), showed significantly prolonged incubation times after infection with RML prions (Table 2) [76]. Further studies are needed to clarify whether or not the OR region might mediate strain-dependent prion pathogenesis.

3.3. The Post-OR Region in Prion Diseases

Three mutations in the post-OR region, including P102L (substitution of a proline residue to a leucine residue at position 102), P105L (substitution of a proline residue to a leucine residue at position 105), and A117V (substitution of an alanine residue to a valine residue at position 117), are associated with inherited human prion diseases [67], suggesting that the post-OR region also plays a role in prion diseases. Tg(PrP-P101L) mice, which express high levels of mouse PrP-P101L, the analogous mutation to human PrP-P102L, have been shown to spontaneously develop prion disease-like diseases, with amyloid plaques, spongiform degeneration, and gliosis in their brains (Table 3) [77]. Brain homogenates from ill Tg(PrP-P101L) mice transmitted the disease to 40% of Tg(PrP-P101L) mice, which never spontaneously developed disease due to lower expression of the mutant protein, and 10% of hamsters, but not to WT CD-1 mice, after intracerebral inoculation (Table 3) [78], indicating that PrP\textsuperscript{Sc}-P101L could be infectious. Tg mice expressing mouse PrP-A116V (the human homologue of PrP-A117V) at six times the endogenous levels of PrP\textsuperscript{C} also spontaneously developed progressive ataxia with vacuolation and PrP amyloid plaques in their brains (Table 3) [79]. The PrP molecules from Tg(PrP-A116V) brains were partly insoluble and weakly protease-resistant (Table 3) [79]. No data are available regarding whether PK-resistant PrP-A116V is infectious. The post-OR region could be also involved in prion infection. Tg(PrP\Delta 32–80)/Prnp0/0 mice developed disease without elongation in incubation times and accumulated PrP\textsuperscript{Sc}Δ32–80 in their brains after infection with RML prions (Table 3) [80], suggesting that residues 32–80 are dispensable for PrP\textsuperscript{C} to convert to PrP\textsuperscript{Sc} after prion infection. However, Tg(PrP\Delta 32–93)/Prnp0/0 mice, which express PrP with a deletion extending to the post-OR region at position 93 from the OR region at position 88, developed disease with longer incubation times and with lower levels of infectivity and PrP\textsuperscript{Sc}Δ32–93 in their brains after infection with RML prions (Table 3) [81]. Moreover, PrP with a deletion further extending to the post-OR region at position 106, or PrP\Delta 32–106, neither converted to PrP\textsuperscript{Sc} nor supported prion pathogenesis in Prnp0/0 mice after intracerebral inoculation with RML prions (Table 3) [82]. These results suggest that the post-OR residues 91–106, which are completely deleted in PrP\Delta 32–106 and partially in PrP\Delta 32–93, but intact in PrP\Delta 32–80, could have a crucial role in prion infection. However, it remains to be determined if the resistance of Tg(PrP\Delta 32–106)/Prnp0/0 mice to RML prions could be due to deletion of the post-OR residues 91–96 alone or together with deletion of other residues.

Table 3. Effects of various mutations in the post-OR region of PrP\textsuperscript{C} on hereditary and acquired prion diseases.

| Disease Type       | PrPs                  | The Post-OR Sequence | Clinicopathological Features                                                                 | References |
|--------------------|-----------------------|----------------------|-----------------------------------------------------------------------------------------------|------------|
| Hereditary prion disease | PrP-P101L             | Proline residue at position 101 mutated to leucine residue in mouse PrP | • Spontaneously develop prion disease-like diseases.  
• Accumulate weakly protease-resistant PrP-P101L in the brain.  
• Accumulate prion infectivity associated with weakly protease-resistant PrP-P101L.  
• Spontaneously developed prion disease-like diseases. | [77,78] |
|                    | PrP-A116V             | Alanine residue at position 116 mutated to valine residue in mouse PrP | • Accumulate partly insoluble and weakly protease-resistant PrP-A116V in the brain.  
• No data available as to infectivity associated with protease-resistant PrP-A116V. | [79] |
4. The N-Terminal Domain in Conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc}

The first step for conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc} is an intermolecular interaction between both molecules. The polybasic region has been suggested to be involved in the binding of PrP\textsuperscript{C} and/or PrP\textsuperscript{Sc} to the extracellular matrix proteins glycosaminoglycans through the positively charged residues [58–60]. It is thus possible that the polybasic region might promote interaction between PrP\textsuperscript{C} and PrP\textsuperscript{Sc} by recruiting both molecules to glycosaminoglycans, thereby supporting conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc} (Figure 2A). The polybasic region has also been suggested to mediate a direct interaction between PrP\textsuperscript{C} and PrP\textsuperscript{Sc}, thereby promoting the conversion of PrP\textsuperscript{C} to PrP\textsuperscript{Sc} [63] (Figure 2B).

The next step for conversion is a structural unfolding of the interacting PrP\textsuperscript{C}. PrP\textsuperscript{C} is rich in α-helix structures and soluble in non-ionic detergents [83]. In contrast, PrP\textsuperscript{Sc} is abundant in β-sheet structures and insoluble in non-ionic detergents, forming fibrils [83], suggesting that structural transition of α-helices to β-sheets in PrP\textsuperscript{C} is an underlying mechanism of the conversion to PrP\textsuperscript{Sc}. Several structural models have been proposed for PrP\textsuperscript{Sc} fibrils. The 4-rung β-solenoid model postulates that a PrP\textsuperscript{Sc} fibril consists of two intertwined protofilaments of PrP\textsuperscript{Sc} molecules [84,85]. In this model, single PrP\textsuperscript{Sc} molecules adopt a solenoid structure of four rungs, each rung including three β-strands, running perpendicular to fibril axis, stacking each other. The upper and lower β-solenoid rungs of PrP\textsuperscript{Sc}...
protofibrils could template an incoming unfolded PrP<sup>C</sup> molecule to create additional β-solenoid rungs. Once a new β-solenoid rung has formed, it continues to template until the unfolded PrP<sup>C</sup> molecule is completely converted to PrP<sup>Sc</sup> conformer. In the parallel in-register intermolecular β-sheet model, single PrP<sup>Sc</sup> molecules comprise the entire cross-section of a fibril, with many hairpins defined by natural and artificial disulfide bonds [86,87]. They are stacked parallel in-register and perpendicular to the fibril axis by forming intermolecular β-sheet interactions between them. Endocytic/lysosomal compartments are considered to be a site for conversion of PrP<sup>C</sup> to PrP<sup>Sc</sup> [88,89], suggesting that acidic conditions in the endosomal/lysosomal compartments might promote the structural unfolding of PrP<sup>C</sup>. The polybasic and OR regions are involved in endocytosis of PrP<sub>Ctm</sub> prion diseases. However, prion disease-like neurodegeneration with focal vacuolar degeneration in the neuropil and astrocytic gliosis [94]. Moreover, the ratio of neuronal cells [94]. Interestingly, transgenic mice expressing these mutant PrPs spontaneously develop cerebellar neurodegeneration, transgenic for PrP with a deletion of the N-terminal residues 32–121 or 32–134, which includes the OR region and a section of the post-OR region, spontaneously developed cerebellar neurodegeneration [96,97], suggesting that structural instability of the OR region or mutations in the post-OR region are associated with spontaneous conversion of mutated PrPs to pathogenic PrPs, causing hereditary prion diseases in humans [67], suggesting that structural instability of the OR region or mutations in the post-OR region might also be involved in the unfolding of the mutant PrPs (Figure 2D,E). Indeed, recombinant human PrPs with three or five extra OR sequences have been reported to spontaneously form aggregates [91]. Copper binding to recombinant mouse PrP was reported to cause novel intramolecular interactions, including those between the N-terminal residues 90–120 and the C-terminal residues 144–147 and its nearby residues 139–143, and between the N-terminal region comprising the OR region and the C-terminal residues 174–185 [92], suggesting that copper binding binding might also involve in the unfolding of PrP<sup>C</sup>. Copper is able to bind to histidine residues located in the OR and post-OR regions [76]. We have shown that, while Tg(PrP<sup>ΔOR</sup>)/Prnp<sup>0/0</sup> mice were highly resistant to BSE prions, they still remained susceptible to RML and 22L prions [70], suggesting that copper binding to histidine residues in the OR region might be irrelevant to the unfolding of PrP<sup>C</sup>. Indeed, it has been shown that histidine residues in the post-OR could be important for conversion of PrP<sup>C</sup> to PrP<sup>Sc</sup> in acidic conditions [93].

5. The N-Terminal Domain and Neurotoxic PrP Molecules

The neurotoxic mechanism of PrP<sup>Sc</sup> remains largely unknown. However, there have been several reports of neurotoxic PrP molecules causing prion disease-like neurodegeneration, giving rise to an interesting possibility that these neurotoxic PrP molecules might share their neurotoxic mechanism with PrP<sup>Sc</sup>. In addition to a GPI-anchored extracellular form of PrP<sup>C</sup>, another form of PrP<sub>C</sub> termed C<sub>mm</sub>PrP, has been reported [94]. C<sub>mm</sub>PrP is a transmembrane form of PrP, with the N-terminus facing the cytoplasm and the C-terminus exposed extracellularly. Increased hydrophobicity in the post-OR region by mutations that cause residues to become hydrophobic, including the mutation in hereditary prion disease (A117V), increase the ratio of C<sub>mm</sub>PrP to total forms of PrP molecules in neuronal cells [94]. Interestingly, transgenic mice expressing these mutant PrPs spontaneously develop prion disease-like neurodegeneration with focal vacuolar degeneration in the neuropil and astrocytic gliosis [94]. Moreover, the ratio of C<sub>mm</sub>PrP was also reported to increase in the brains of mice infected with prions [95]. These results suggest that C<sub>mm</sub>PrP might be responsible for neurodegeneration in prion diseases. However, C<sub>mm</sub>PrP from transgenic mice is not infectious [94].

Other neurotoxic PrP molecules have also been reported. It was shown that Prnp<sup>0/0</sup> mice transgenic for PrP with a deletion of the N-terminal residues 32–121 or 32–134, which includes the OR region and a section of the post-OR region, spontaneously developed cerebellar neurodegeneration, with marked granule cell death [96]. Other investigators also showed that Prnp<sup>0/0</sup> mice expressing a PrP molecule, designated ACR, that harbors a deletion of residues 105–125, developed cerebellar neurodegeneration [97], suggesting that deletion of the post-OR residues 105–125 alone could be responsible for the neurodegeneration in Prnp<sup>0/0</sup> mice expressing PrPA21–121 and PrPA32–134. Interestingly, the neurotoxicity of these mutant PrPs in Prnp<sup>0/0</sup> mice is abrogated by co-expression of WT PrP<sup>C</sup> [96,97], suggesting that, while the toxic PrP molecules generate a neurotoxic signal, WT PrP<sup>C</sup> transduces a neuroprotective signal to antagonize the neurotoxic signal of the mutant PrPs. It was
shown that, in contrast to PrPΔ32–134, PrPΔ23–134 was not neurotoxic in Prnp0/0 mice, suggesting that the polybasic region residues 23–31, which remain intact in toxic PrPΔ32–134 but not in non-toxic PrPΔ23–134, are critical for the neurotoxicity of mutant PrPs [98,99]. Patch-clamp electrophysiological experiments revealed that ΔCR induced abnormal spontaneous ionic currents in various cultured cells and neurons through the polybasic region, and that these currents were suppressed by co-expression of WT PrP[C] [100,101], suggesting that the abnormal ionic currents might be the neurotoxic signal of the mutant PrPs. It would be thus worthy to investigate whether PrPSc could generate similar abnormal currents in neurons.

6. Conclusions

It has been shown that the non-structural, flexible N-terminal domain, which includes various specific regions such as the polybasic region, OR regions, and post-OR region, has a role in not only the normal function of PrP[C] but also in the pathogenesis of prion diseases through regulation of the conversion of PrP[C] to PrPSc and the neurotoxicity of PrPSc. Further elucidation of the exact mechanism of how each of the N-terminal regions could regulate the normal function of PrP[C] and prion pathogenesis would be of great help for understanding the function of PrP[C] and prion pathogenesis, and eventually for developing therapeutics for prion diseases.

Author Contributions: Conceptualization, H.H. and S.S.; writing, H.H. and S.S.; funding acquisition, H.H. and S.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported in part by JSPS KAKENHI Grant Number 18K07499, Brain Science Foundation, Takeda Science Foundation, and The Ichiro Kanehara Foundation to H.H. and JSPS KAKENHI Grant Number 19H03548 to S.S.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

PrP: Prion protein
OR: Octapeptide repeat
WT: Wild-type
CJD: Creutzfeldt-Jakob disease

References

1. Aguzzi, A.; Baumann, F.; Bremer, J. The prion’s elusive reason for being. Annu. Rev. Neurosci. 2008, 31, 439–477. [CrossRef] [PubMed]
2. Prusiner, S.B. The prion diseases. Brain Pathol. 1998, 8, 499–513. [CrossRef] [PubMed]
3. Scheckel, C.; Aguzzi, A. Prions, prionoids and protein misfolding disorders. Nat. Rev. Genet. 2018, 19, 405–418. [CrossRef] [PubMed]
4. Giles, K.; Olson, S.H.; Prusiner, S.B. Developing Therapeutics for PrP Prion Diseases. Cold Spring Harb. Perspect. Med. 2017, 7, a023747. [CrossRef] [PubMed]
5. Prusiner, S.B. Early evidence that a protease-resistant protein is an active component of the infectious prion. Cell 2004, 116, S109. [CrossRef]
6. Prusiner, S.B. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216, 136–144. [CrossRef]
7. Igel-Egalon, A.; Bohl, J.; Moudjou, M.; Herzog, L.; Reine, F.; Rezaei, H.; Beringue, V. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process? Viruses 2019, 11, 429. [CrossRef]
8. Bueler, H.; Aguzzi, A.; Sailer, A.; Greiner, R.A.; Autenried, P.; Aguet, M.; Weissmann, C. Mice devoid of PrP are resistant to scrapie. Cell 1993, 73, 1339–1347. [CrossRef]
9. Prusiner, S.B.; Groth, D.; Serban, A.; Koehler, R.; Foster, D.; Torchia, M.; Burton, D.; Yang, S.L.; DeArmond, S.J. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl. Acad. Sci. USA 1993, 90, 10608–10612. [CrossRef]
10. Manson, J.C.; Clarke, A.R.; McBride, P.A.; McConnell, I.; Hope, J. PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. *Neurodegeneration* 1994, 3, 331–340.

11. Sakaguchi, S.; Katamine, S.; Shigematsu, K.; Nakatani, A.; Moriuchi, R.; Nishida, N.; Kurokawa, K.; Nakaoke, R.; Sato, H.; Jishage, K.; et al. Accumulation of protease K-resistant prion protein (PrP) is restricted by the expression level of normal PrP in mice inoculated with a mouse-adapted strain of the Creutzfeldt-Jakob disease agent. *J. Virol.* 1995, 69, 7586–7592. [CrossRef] [PubMed]

12. Schatzl, H.M.; Da Costa, M.; Taylor, L.; Cohen, F.E.; Prusiner, S.B. Prion protein gene variation among primates. *J. Mol. Biol.* 1995, 245, 362–374. [CrossRef] [PubMed]

13. Oesch, B.; Westaway, D.; Walchli, M.; McKinley, M.P.; Kent, S.B.; Aebersold, R.; Barry, R.A.; Tempst, P.; Teplow, D.B.; Hood, L.E.; et al. A cellular gene encodes scrapie PrP 27–30 protein. *Cell.* 1985, 40, 735–746. [CrossRef]

14. Riek, R.; Hornemann, S.; Wider, G.; Glockshuber, R.; Wuthrich, K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23–231). *FEBS Lett.* 1997, 413, 282–288. [CrossRef]

15. Donne, D.G.; Viles, J.H.; Groth, D.; Mehlhorn, I.; James, T.L.; Cohen, F.E.; Prusiner, S.B.; Wright, P.E.; Dyson, H.J. Structure of the recombinant full-length hamster prion protein PrP(29–231): The N terminus is highly flexible. *Proc. Natl. Acad. Sci. USA* 1997, 94, 13452–13457. [CrossRef] [PubMed]

16. Calzolai, L.; Lysek, D.A.; Perez, D.R.; Guntert, P.; Wuthrich, K. Prion protein NMR structures of chickens, turtles, and frogs. *Proc. Natl. Acad. Sci. USA* 2005, 102, 651–655. [CrossRef] [PubMed]

17. Prusiner, S.B. Molecular biology of prion diseases. *Science* 1991, 252, 1515–1522. [CrossRef]

18. Hackl, S.; Becker, C.F.W. Prion protein-Semisynthetic prion protein (PrP) variants with posttranslational modifications. *J. Pept. Sci.* 2019, 25, e3216. [CrossRef]

19. Stahl, N.; Borchelt, D.R.; Hsiao, K.; Prusiner, S.B. Scrapie prion protein contains a phosphatidylinositol glycolipid. *Cell* 1987, 51, 229–240. [CrossRef]

20. Hebert, D.N.; Molinari, M. In and out of the ER: Protein folding, quality control, degradation, and related human diseases. *Physiol. Rev.* 2007, 87, 1377–1408. [CrossRef] [PubMed]

21. Rapoport, T.A. Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. *Nature* 2007, 450, 663–669. [CrossRef] [PubMed]

22. Needham, P.G.; Guerriero, C.J.; Brodsky, J.L. Chaperoning Endoplasmic Reticulum-Associated Degradation (ERAD) and Protein Conformational Diseases. *Cold Spring Harb. Perspect. Biol.* 2019, 11, a033928. [CrossRef] [PubMed]

23. Puig, B.; Altmeppen, H.C.; Linsenmeier, L.; Chakroun, K.; Wegwitz, F.; Piontek, U.K.; Tatzelt, J.; Bate, C.; Magnus, T.; Glatzel, M. GPI-anchor signal sequence influences PrP<sup>Sc</sup> sorting, shedding and signalling, and impacts on different pathomechanistic aspects of prion disease in mice. *PLoS Pathog.* 2019, 15, e1007520. [CrossRef]

24. Wulf, M.A.; Senatore, A.; Aguzzi, A. The biological function of the cellular prion protein: An update. *BMC Biol.* 2017, 15, 34. [CrossRef]

25. Peters, P.J.; Mironov, A., Jr.; Peretz, D.; van Donselaar, E.; Leclerc, E.; Erpel, S.; DeArmond, S.J.; Burton, D.R.; Williamson, R.A.; Vey, M.; et al. Trafficking of prion proteins through a caveolae-mediated endosomal pathway. *J. Cell Biol.* 2003, 162, 703–717. [CrossRef]

26. Campana, V.; Sarnataro, D.; Zurzolo, C. The highways and byways of prion protein trafficking. *Trends Cell Biol.* 2005, 15, 102–111. [CrossRef]

27. Vilette, D.; Courte, J.; Peyrin, J.M.; Coudert, L.; Schaeffer, L.; Andreoletti, O.; Leblanc, P. Cellular mechanisms responsible for cell-to-cell spreading of prions. *Cell Mol. Life Sci.* 2018, 75, 2557–2574. [CrossRef] [PubMed]
31. Uchiyama, K.; Tomita, M.; Yano, M.; Chida, J.; Hara, H.; Das, N.R.; Nykjaer, A.; Sakaguchi, S. Prions amplify through degradation of the VPS10P sorting receptor sortilin. *PloS Pathog.* 2017, 13, e1006470. [CrossRef] [PubMed]
32. Taylor, D.R.; Hooper, N.M. The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. *Biochem. J.* 2007, 402, 17–23. [CrossRef]
33. Bueler, H.; Fischer, M.; Lang, Y.; Bluethmann, H.; Lipp, H.P.; DeArmond, S.J.; Prusiner, S.B.; Aguet, M.; Weissmann, C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. *Nature* 1992, 356, 577–582. [CrossRef] [PubMed]
34. Manson, J.C.; Clarke, A.R.; Hooper, M.L.; Aitchison, L.; McConnell, I.; Hope, J. 129
35. Nishida, N.; Katamine, S.; Shigematsu, K.; Nakatani, A.; Sakamoto, N.; Hasegawa, S.; Nakaoka, R.; Atarashi, R.; Kataoka, Y.; Miyamoto, T. Prion protein is necessary for latent learning and long-term memory retention. *Cell Mol. Neurobiol.* 1997, 17, 537–545. [CrossRef] [PubMed]
36. Collinge, J.; Whittington, M.A.; Sidle, K.C.; Smith, C.J.; Palmer, M.S.; Clarke, A.R.; Jefferys, J.G. Prion protein is necessary for normal synaptic function. *Nature* 1994, 370, 295–297. [CrossRef]
37. Tobler, I.; Gaus, S.E.; Deboer, T.; Achermenn, P.; Fischer, M.; Rulicke, T.; Moser, M.; Oesch, B.; McBride, P.A.; Manson, J.C. Altered circadian activity rhythms and sleep in mice devoid of prion protein. *Nature* 1996, 380, 639–642. [CrossRef]
38. Nishida, N.; Tremblay, P.; Sugimoto, T.; Shigematsu, K.; Shirabe, S.; Petromilli, C.; Erpel, S.P.; Nakaoka, R.; Atarashi, R.; Houtani, T.; et al. A mouse prion protein transgene rescues mice deficient for the prion protein gene from purkinje cell degeneration and demyelination. *Lab. Investig.* 1999, 79, 689–697.
39. Kim, C.K.; Sakudo, A.; Taniuchi, Y.; Shigematsu, K.; Lang, Y.; Bluethmann, H.; Lipp, H.P.; DeArmond, S.J.; Prusiner, S.B.; Aguet, M.; Weissmann, C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. *Nature* 1992, 356, 577–582. [CrossRef] [PubMed]
40. Le Pichon, C.E.; Valley, M.T.; Polymenidou, M.; Chesler, A.T.; Sagdullaev, B.T.; Aguzzi, A.; Firestein, S. Olfactory behavior and physiology are disrupted in prion protein knockout mice. *Nat. Neurosci.* 2009, 12, 60–69. [CrossRef]
41. Lledo, P.M.; Tremblay, P.; DeArmond, S.J.; Prusiner, S.B.; Nicoll, R.A. Mice deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in the hippocampus. *Proc. Natl. Acad. Sci. USA* 1996, 93, 2403–2407. [CrossRef] [PubMed]
42. Weise, J.; Crome, O.; Sandau, R.; Schulz-Schaeffer, W.; Bahr, M.; Zerr, I. Upregulation of cellular prion protein (PrP(C)) after focal cerebral ischemia and influence of lesion severity. *Neurosci. Lett.* 2004, 372, 146–150. [CrossRef] [PubMed]
43. McLennan, N.F.; Brennan, P.M.; McNell, A.; Davies, I.; Fotheringham, A.; Rennison, K.A.; Ritchie, D.; Brannan, F.; Head, M.W.; Ironside, J.W.; et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. *Am. J. Pathol.* 2004, 165, 227–235. [CrossRef]
44. Sakurai-Yamashita, Y.; Sakaguchi, S.; Yoshikawa, D.; Okimura, N.; Masuda, Y.; Katamine, S.; Niwa, M. Female-specific neuroprotection against transient brain ischemia observed in mice devoid of prion protein is abolished by ectopic expression of prion protein-like protein. *Neuroscience* 2005, 136, 281–287. [CrossRef] [PubMed]
45. Zhang, B.; Cowden, D.; Zhang, F.; Yuan, J.; Siedlak, S.; Abouelsaad, M.; Zeng, L.; Zhou, X.; O’Toole, J.; Das, A.S.; et al. Prion Protein Protects against Renal Ischemia/Reperfusion Injury. *PloS ONE* 2015, 10, e0136923.
46. Zanetti, F.; Carpi, A.; Menabo, R.; Giorgio, M.; Schulz, R.; Valen, G.; Baysa, A.; Massimino, M.L.; Sorgato, M.C.; Bertoli, A.; et al. The cellular prion protein counteracts cardiac oxidative stress. *Cardiovasc. Res.* 2014, 104, 93–102. [CrossRef]
47. Chida, J.; Hara, H.; Yano, M.; Uchiyama, K.; Das, N.R.; Takahashi, E.; Miyata, H.; Tomioka, Y.; Ito, T.; Kido, H.; et al. Prion protein protects mice from lethal infection with influenza A viruses. *PloS Pathog.* 2018, 14, e1007049. [CrossRef] [PubMed]
48. Mitteregger, G.; Vosko, M.; Krebs, B.; Xiang, W.; Kohlmannsperger, V.; Nolting, S.; Hamann, G.F.; Kretzschmar, H.A. The role of the octarepeat region in neuroprotective function of the cellular prion protein. *Brain Pathol.* 2007, 17, 174–183. [CrossRef] [PubMed]
49. Brown, D.R.; Qin, K.; Herms, J.W.; Madlung, A.; Manson, J.; Strome, R.; Fraser, P.E.; Kruck, T.; von Bohlen, A.; Schulz-Schaeffer, W.; et al. The cellular prion protein binds copper in vivo. *Nature* **1997**, *390*, 684–687. [CrossRef] [PubMed]

50. Brown, D.R.; Wong, B.S.; Hafiz, F.; Clive, C.; Haswell, S.J.; Jones, I.M. Normal prion protein has an activity like that of superoxide dismutase. *Biochem. J.* **1999**, *344*, 1–5. [CrossRef]

51. Jones, S.; Batchelor, M.; Behlt, D.; Clarke, A.R.; Collinge, J.; Jackson, G.S. Recombinant prion protein does not possess SOD-1 activity. *Biochem. J.* **2003**, *392*, 309–312. [CrossRef] [PubMed]

52. Hutter, G.; Heppner, F.L.; Aguzzi, A. No superoxide dismutase activity of cellular prion protein In vivo. *J. Biol. Chem.* **2003**, *384*, 1279–1285. [CrossRef]

53. Bounhar, Y.; Zhang, Y.; Goodyer, C.G.; LeBlanc, A. Prion protein protects human neurons against Bax-mediated apoptosis. *J. Biol. Chem.* **2001**, *276*, 39145–39149. [CrossRef]

54. Osiecka, K.M.; Nieznanska, H.; Skowronek, J.K.; Karolczak, J.; Schneider, G.; Nieznanski, K. Prion protein region 23–32 interacts with tubulin and inhibits microtubule assembly. *Proteins* **2009**, *77*, 279–296. [CrossRef]

55. Pan, T.; Wong, B.S.; Liu, T.; Li, R.; Petersen, R.B.; Sy, M.S. Cell-surface prion protein interacts with glycosaminoglycans. *Biochem. J.* **2002**, *368*, 81–90. [CrossRef]

56. Haigh, C.L.; Tumpach, C.; Drew, S.C.; Collins, S.J. The Prion Protein N1 and N2 Cleavage Fragments Bind to Phosphatidylserine and Phosphatidic Acid; Relevance to Stress-Protection Responses. *PLoS ONE* **2015**, *10*, e0134680. [CrossRef]

57. Parkin, E.T.; Watt, N.T.; Hussain, I.; Eckman, E.A.; Eckman, C.B.; Manson, J.C.; Baybutt, H.N.; Turner, A.J.; Warner, R.G.; Hundt, C.; Weiss, S.; Turnbull, J.E. Identification of the heparan sulfate binding sites in the cellular prion protein. *J. Biol. Chem.* **2002**, *277*, 18421–18430. [CrossRef]

58. Pan, T.; Wong, B.S.; Liu, T.; Li, R.; Petersen, R.B.; Sy, M.S. Cell-surface prion protein interacts with glycosaminoglycans. *Biochem. J.* **2002**, *368*, 81–90. [CrossRef]

59. Warner, R.G.; Hundt, C.; Weiss, S.; Turnbull, J.E. Identification of the heparan sulfate binding sites in the cellular prion protein. *J. Biol. Chem.* **2002**, *277*, 18421–18430. [CrossRef]

60. Taubner, L.M.; Biemkiewicz, E.A.; Copie, V.; Caughey, B. Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan. *J. Mol. Biol.* **2010**, *395*, 475–490. [CrossRef]

61. Parkin, E.T.; Watt, N.T.; Hussain, I.; Eckman, E.A.; Eckman, C.B.; Manson, J.C.; Baybutt, H.N.; Turner, A.J.; Hooper, N.M. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor protein. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 11062–11067. [CrossRef] [PubMed]

62. Bravard, A.; Auvre, F.; Fantini, D.; Bernardino-Sgherri, J.; Sissoeff, L.; Daynac, M.; Xu, Z.; Etienne, O.; Dehen, C.; Comoy, E.; et al. The prion protein is critical for DNA repair and cell survival after genotoxic stress. *Nucleic Acids Res.* **2015**, *43*, 904–916. [CrossRef] [PubMed]

63. Turnbaugh, J.A.; Unterberger, U.; Saa, P.; Massignan, T.; Fluharty, B.R.; Bowman, F.P.; Miller, M.B.; Supattapone, S.; Biasini, E.; Harris, D.A. The N-terminal, polybasic region of PrP<sup>C</sup> dictates the efficiency of prion propagation by binding to PrP<sup>C</sup>. *J. Neurosci.* **2012**, *32*, 8817–8830. [CrossRef] [PubMed]

64. Das, N.R.; Miyata, H.; Hara, H.; Uchiyama, K.; Chida, J.; Yano, M.; Watanabe, H.; Kondoh, G.; Sakaguchi, S. Effects of prion protein devoid of the N-terminal residues 25–50 on prion pathogenesis in mice. *Arch. Virol.* **2017**, *162*, 1867–1876. [CrossRef] [PubMed]

65. Khalife, M.; Reine, F.; Paquet-Fifield, S.; Castille, J.; Herzog, L.; Villette, M.; Moudjou, M.; Moazami-Goudarzi, K.; Makhzami, S.; Passet, B.; et al. Mutated but Not Deleted Ovine PrP<sup>C</sup>-N-Terminal Polybasic Region Strongly Interferes with Prion Propagation in Transgenic Mice. *J. Virol.* **2016**, *90*, 1638–1646. [CrossRef]

66. Das, N.R.; Miyata, H.; Hara, H.; Chida, J.; Uchiyama, K.; Masujin, K.; Watanabe, H.; Kondoh, G.; Sakaguchi, S. The N-Terminal Polybasic Region of Prion Protein Is Crucial in Prion Pathogenesis Independently of the Octapeptide Repeat Region. *Mol. Neurobiol.* **2020**, *57*, 1203–1216. [CrossRef]

67. Prusiner, S.B. Genetic and infectious prion diseases. *Arch. Neurol.* **1993**, *50*, 1129–1153. [CrossRef]

68. Brown, P.; Gibbs, C.J., Jr.; Rodgers-Johnson, P.; Asher, D.M.; Sulima, M.P.; Bacote, A.; Goldfarb, L.G.; Gajdusek, D.C. Human spongiform encephalopathy: The National Institutes of Health series of 300 cases of experimentally transmitted disease. *Ann. Neurol.* **1994**, *35*, 513–529. [CrossRef]
69. Yamaguchi, Y.; Miyata, H.; Uchiyama, K.; Ootsuyama, A.; Inubushi, S.; Mori, T.; Muramatsu, N.; Katamine, S.; Sakaguchi, S. Biological and biochemical characterization of mice expressing prion protein devoid of the octapeptide repeat region after infection with prions. *PloS ONE* **2012**, *7*, e43540. [CrossRef]

70. Hara, H.; Miyata, H.; Das, N.R.; Chida, J.; Yoshimochi, T.; Uchiyama, K.; Watanabe, H.; Kondoh, G.; Yokoyama, T.; Sakaguchi, S. Prion Protein Devoid of the Octapeptide Repeat Region Delays Bovine Spongiform Encephalopathy Pathogenesis in Mice. *J. Virol.* **2017**, *92*, e01368-17. [CrossRef]

71. Chiesa, R.; Piccardo, P.; Ghetti, B.; Harris, D.A. Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. *Neuron* **1998**, *21*, 1339–1351. [CrossRef]

72. Chiesa, R.; Drisaldi, B.; Quaglio, E.; Migheli, A.; Piccardo, P.; Ghetti, B.; Harris, D.A. Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 5574–5579. [CrossRef] [PubMed]

73. Biasini, E.; Seegulam, M.E.; Patti, B.N.; Solforosi, L.; Medrano, A.Z.; Christensen, H.M.; Senatore, A.; Chiesa, R.; Williamson, R.A.; Harris, D.A. Non-infectious aggregates of the prion protein react with several PrPNC-Directed antibodies. *J. Neurochem.* **2008**, *105*, 2190–2204. [CrossRef] [PubMed]

74. Castilla, J.; Gutierrez-Adan, A.; Brun, A.; Pintado, B.; Salguero, F.J.; Parra, B.; Segundo, F.D.; Ramirez, M.A.; Rabano, A.; Cano, M.J.; et al. Transgenic mice expressing bovine PrP with a four extra repeat octapeptide insert mutation show a spontaneous, non-transmissible, neurodegenerative disease and an expedited course of BSE infection. *FEBS Lett.* **2005**, *579*, 6237–6246. [CrossRef]

75. Castilla, J.; Gutierrez-Adan, A.; Brun, A.; Pintado, B.; Parra, B.; Ramirez, M.A.; Salguero, F.J.; Diaz San Segundo, F.; Rabano, A.; Cano, M.J.; et al. Different behavior toward bovine spongiform encephalopathy infection of bovine prion protein transgenic mice with one extra repeat octapeptide insert mutation. *J. Neurosci.* **2008**, *24*, 2156–2164. [CrossRef]

76. Eigenbrod, S.; Frick, P.; Bertsch, U.; Mitteregger-Kretzschmar, G.; Mielke, J.; Maringer, M.; Piening, N.; Hepp, A.; Daude, N.; Windl, O.; et al. Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice. *PloS ONE* **2017**, *12*, e0188989. [CrossRef]

77. Hsiao, K.K.; Scott, M.; Foster, D.; Groth, D.F.; DeArmond, S.J.; Prusiner, S.B. Spontaneous neurodegeneration in transgenic mice with mutant prion protein. *Science* **1990**, *250*, 1587–1590. [CrossRef]

78. Hsiao, K.K.; Groth, D.; Scott, M.; Yang, S.L.; Serban, A.; Rapp, D.; Foster, D.; Torchia, M.; Dearmond, S.J.; Prusiner, S.B. Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 9126–9130. [CrossRef]

79. Yang, W.; Cook, J.; Rassbach, B.; Lemus, A.; DeArmond, S.J.; Mastrianni, J.A. A New Transgenic Mouse Model of Gerstmann-Sträussler-Scheinker Syndrome Caused by the A117V Mutation of PRNP. *J. Neurosci.* **2009**, *29*, 10072–10080. [CrossRef] [PubMed]

80. Fischer, M.; Rulicke, T.; Raebel, A.; Sailer, A.; Moser, M.; Oesch, B.; Brandner, S.; Aguzzi, A.; Weissmann, C. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. *EMBO J.* **1996**, *15*, 1255–1264. [CrossRef]

81. Flechsig, E.; Shmerling, D.; Hegyi, I.; Raebel, A.J.; Fischer, M.; Cozzio, A.; von Mering, C.; Aguzzi, A.; Weissmann, C. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. *Neuron* **2002**, *27*, 399–408. [CrossRef]

82. Weissmann, C.; Flechsig, E. PrP knock-out and PrP transgenic mice in prion research. *Br. Med. Bull.* **2003**, *66*, 43–60. [CrossRef] [PubMed]

83. Pan, K.M.; Baldwin, M.; Nguyen, J.; Gasset, M.; Serban, A.; Groth, D.; Mehlinhorn, I.; Huang, Z.; Fletterick, R.J.; Cohen, F.E.; et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 10962–10966. [CrossRef] [PubMed]

84. Wille, H.; Bain, W.; McDonald, M.; Kendall, A.; Colby, D.W.; Bloch, L.; Ollesch, J.; Borovskiy, A.L.; Cohen, F.E.; Prusiner, S.B.; et al. Natural and synthetic prion structure from X-ray fiber diffraction. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 16990–16995. [CrossRef] [PubMed]

85. Vazquez-Fernandez, E.; Vos, M.R.; Afanasyev, P.; Cebeby, L.; Sevillano, A.M.; Vidal, E.; Rosa, I.; Renault, L.; Ramos, A.; Peters, P.J.; et al. The Structural Architecture of an Infectious Mammalian Prion Using Electron Cryomicroscopy. *PLoS Pathog.* **2016**, *12*, e1005835. [CrossRef] [PubMed]

86. Baskakov, I.V.; Caughey, B.; Requena, J.R.; Sevillano, A.M.; Surewicz, W.K.; Wille, H. The prion 2018 round tables (I): The structure of PrPNC. *Prion* **2019**, *13*, 46–52. [CrossRef]
87. Spagnolli, G.; Rigoli, M.; Orioli, S.; Sevillano, A.M.; Faccioli, P.; Wille, H.; Biasini, E.; Requena, J.R. Full atomistic model of prion structure and conversion. *PLoS Pathog.* **2019**, *15*, e1007864. [CrossRef]

88. Caughey, B.; Raymond, G.J.; Ernst, D.; Race, R.E. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): Implications regarding the site of conversion of PrP to the protease-resistant state. *J. Virol.* **1991**, *65*, 6597–6603. [CrossRef]

89. Borchelt, D.R.; Taraboulos, A.; Prusiner, S.B. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. *J. Biol. Chem.* **1992**, *267*, 16188–16199.

90. Walmsley, A.R.; Zeng, F.; Hooper, N.M. The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant. *J. Biol. Chem.* **2003**, *278*, 37241–37248. [CrossRef]

91. Yu, S.; Yin, S.; Li, C.; Wong, P.; Chang, B.; Xiao, F.; Kang, S.C.; Yan, H.; Xiao, G.; Tien, P.; et al. Aggregation of prion protein with insertion mutations is proportional to the number of inserts. *Biochem. J.* **2007**, *403*, 343–351. [CrossRef] [PubMed]

92. Thakur, A.K.; Srivastava, A.K.; Srinivas, V.; Chary, K.V.; Rao, C.M. Copper alters aggregation behavior of prion protein and induces novel interactions between its N- and C-terminal regions. *J. Biol. Chem.* **2011**, *286*, 38533–38545. [CrossRef] [PubMed]

93. Giachin, G.; Mai, P.T.; Tran, T.H.; Salzano, G.; Benetti, F.; Migliorati, V.; Arcovito, A.; Della Longa, S.; Mancini, G.; D’Angelo, P.; et al. The non-octarepeat copper binding site of the prion protein is a key regulator of prion conversion. *Sci. Rep.* **2015**, *5*, 15253. [CrossRef] [PubMed]

94. Hegde, R.S.; Mastrianni, J.A.; Scott, M.R.; DeFea, K.A.; Tremblay, P.; Torchia, M.; DeArmond, S.J.; Prusiner, S.B.; Lingappa, V.R. A transmembrane form of the prion protein in neurodegenerative disease. *Science* **1998**, *279*, 827–834. [CrossRef]

95. Hegde, R.S.; Tremblay, P.; Groth, D.; DeArmond, S.J.; Prusiner, S.B.; Lingappa, V.R. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. *Nature* **1999**, *402*, 822–826. [CrossRef]

96. Shmerling, D.; Hegyi, I.; Fischer, M.; Blatlter, T.; Brandner, S.; Gotz, J.; Rulicke, T.; Flechsig, E.; Cozzio, A.; von Mering, C.; et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. *Cell* **1998**, *93*, 203–214. [CrossRef]

97. Li, A.; Christensen, H.M.; Stewart, L.R.; Roth, K.A.; Chiesa, R.; Harris, D.A. Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105–125. *EMBO J.* **2007**, *26*, 548–558. [CrossRef]

98. Westergard, L.; Turnbaugh, J.A.; Harris, D.A. A nine amino acid domain is essential for mutant prion protein toxicity. *J. Neurosci.* **2011**, *31*, 14005–14017. [CrossRef]

99. Turnbaugh, J.A.; Westergard, L.; Unterberger, U.; Biasini, E.; Harris, D.A. The N-terminal, polybasic region is critical for prion protein neuroprotective activity. *PLoS ONE* **2011**, *6*, e25675. [CrossRef]

100. Solomon, I.H.; Khatri, N.; Biasini, E.; Massignan, T.; Huettner, J.E.; Harris, D.A. An N-terminal polybasic domain and cell surface localization are required for mutant prion protein toxicity. *J. Biol. Chem.* **2011**, *286*, 14724–14736. [CrossRef] [PubMed]

101. Wu, B.; McDonald, A.J.; Markham, K.; Rich, C.B.; McHugh, K.P.; Tatzelt, J.; Colby, D.W.; Millhauser, G.L.; Harris, D.A. The N-terminus of the prion protein is a toxic effector regulated by the C-terminus. *Elife* **2017**, *6*, e23473. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).